There is no cross-resistance with clinically used antibiotics. A-16686, administered subcutaneously, is very effective in experimental S. pyogenes and S. pneumoniae septicemias in the mouse. Antibiotic A-16686, a complex of three closely related polypeptides containing chlorinated phenyl moieties, was obtained from fermentation of Actinoplanes sp. ATCC 330761.
In this report we present data on the in vitro and in vivo antibacterial activity of this antibiotic.
Materials and Methods

Antibiotics
A-16686 was dissolved in distilled water. Its activity was compared with those of cephaloridine, ampicillin, erythromycin and vancomycin.
Organisms
Reference strains and 60 Gram-positive clinical isolates were tested; the clinical isolates were obtained from various hospitals and most of them were resistant to one or more clinically used antibiotics, including methicillin.
Media
For susceptibility testing, Oxoid Iso-Sensitest broth was used for most strains and Difco ToddHewitt broth for streptococci; the latter medium was employed for killing curves. Difco brain heart infusion agar and Wilkins-Chalgren agar2) were used for Actinomyces and anaerobes, respectively. Supplemented thioglycolate medium without indicator (BBL-135C) was used to prepare the inoculum of anaerobic bacteria3).
Susceptibility Testing
MIC Determination:
MIC were determined by either the broth or the agar serial two-fold dilution method, with concentrations ranging from 0.002 to 128 p.g/ml. For most strains, overnight broth cultures were diluted to obtain inocula of approximately 104 colony forming units (cfu)/ml.
The tubes were incubated at 37°C for 18 -24 hours. For anaerobic bacteria, plates containing antibiotic were inoculated, using a multipoint inoculator (H 400 Denley Instruments Ltd), with 48-hour broth cultures, diluted 1 : 10. Incubation was for 48 hours in an atmosphere of N2: CO2: H2 (80: 10: 10).
The MIC was taken as the lowest concentration of antibiotic which prevented visible growth.
Some of these data were presented at the 13th International Congress of Chemotherapy, Vienna, August 28, 1983.
Effect of pH, Serum and Inoculum Size on MIC: The broth dilution method was used. pH's ranged from 6 to 9 and bovine serum concentrations from 10 to 70%; inoculum sizes ranged from 10} to 107 cfu/ml.
Cross-resistance Determination: Cross-resistance was evaluated by determining MIC of A-16686 for mutants of Staphylococcus aureus ATCC 6538 resistant to various antibiotics.
Bactericidal Activity Killing Curves: Growing Cells: Various concentrations of A-16686, ampicillin and vancomycin were added to growing cells of S. aureus L1532, S. epidermidis L1578, Streptococcus faecalis L1362, S. faecium var. durans L1584, S. mills L796, S. mutans L659, S. bovis L1325 and S. sanguis L667.
At intervals during incubation at 37°C, samples were removed and plated to titer surviving bacteria. Stationary Cells: In this case, the antibiotic was added to overnight broth cultures of S. aureus ATCC 6538, which were then further incubated at 37°C for 24 hours.
Experimental Infections The ED50's were determined as described previously°>.
Results
Susceptibility Testing
MIC Determination
A-16686 was very active against Gram-positive aerobic and anaerobic bacteria ( A-16686 showed activity comparable to that of ampicillin but it was slightly less active than cephaloridine and erythromycin.
Particularly noteworthy is A-16686's activity against S. faecalis and S. faecium (MIC range 0.5" 2 jig/ml).
A-16686 had good activity against clinical isolates of staphylococci, most of them resistant to one or more antibiotics including methicillin.
Influence of pH, Inoculum and Serum on the MIC of A-16686
The in vitro activity of A-16686 against clinical isolates of S. aureus, S. epidermidis, S. faecalis and S. pyogenes was not significantly affected by the pH of the medium, the addition of bovine serum or the inoculum size. Only in S. aureus there was a small (four-fold) increase in the MIC when the inoculum was increased from 101 to 107 cfu/ml (Table 3) .
Cross-resistance
No cross-resistance between A-16686 and various clinically used antibiotics was observed on S.
aureus ATCC 6538 mutants (data not shown).
Bactericidal Activity
Killing Curves A-16686 was bactericidal for growing cells but not for non-proliferating cells. After 3 -5 hours of contact with a concentration five times the MIC, 99.9 % of growing cells of S. aureus, S. epidermidis, S. faecalis, S. faecium, S. mitis and S. mutans were killed; killing of S. bovis was less marked (Figs. 1 -7 ).
In contrast, even at 50 times the MIC (10 jig/ml) A-16686 had no bactericidal activity for non-proliferating cells of S. aureus ATCC 6538.
The bactericidal action of A-16686 appeared to be slower against S. sanguis (Fig. 8) ; after 5 hours hardly any effect was observed, but by the next time point (24 hours) 99.9% killing was obtained.
The bactericidal action of A-16686 is largely independent of the concentration used; good killing was obtained at concentrations as low as two times the MIC and more rapid killing was observed at concentrations of ten times the MIC against some strains. • Control A Ampicillin 1.25 pg/ml A A-16686 5 pg/ml L1 Vancomycin 5 pg/ml • Control A Ampicillin 0.625 pg/ml 0 A-16686 5 pg/ml O Vancomycin 2.5 pg/ml Subcutaneously administered A-16686 was very effective in curing mice experimentally infected with S. pyogenes and S. pneumoniae (Table 4) . In these infections, its efficacy was greater than those of the other antibiotics tested, with the exception of cephaloridine in the S. pyogenes infection.
A-16686 was less effective in the S. aureus infection, where it protected 50% of the treated animals at a dose of about 25 mg/kg; this result is comparable to those obtained with erythromycin and benzylpenicillin in the same experimental conditions.
When administered orally in water solution containing either 0.5% Methocel or 7.5% Cetomacrogol 1000, which reportedly increases oral absorption5), A-16686 was not effective at up to 200 mg/kg in the S. pyogenes infection. The in vitro and in vivo activities of the three components') of the complex, Al, A2 and A3, were determined. Each of them had in vitro activity similar to that of the complex. In experimental septicemias, Al and A2 showed activity similar to that of the complex, while A3 was slightly less effective (Table 5 ). These studies show that A-16686 has good in vitro activity against staphylococci (including methicillin-resistant isolates), streptococci, Actinomyces and Gram-positive anaerobes. Although less active than cephaloridine, ampicillin and erythromycin against most strains of streptococci, it is generally more active against S. faecalis and S. faecium.
Of particular interest is its marked and rapid bactericidal activity against several species including staphylococci, S. faecalis, S. faecium, S. mutans and S. mitis and its good, if less rapid, killing of S. sanguis. Other interesting features are its excellent therapeutic activity in curing experimental septicemias in the mouse and the lack of cross-resistance with clinically used antibiotics.
A-16686 appears to be a promising antibiotic for the therapy of infections caused by Gram-positive bacteria.
